Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3703681 | 1.00 | TAAR1 (0.40) | TAAR1APPAOC3SHBGKIF11 | |
| SCHEMBL6563465 | 0.89 | AOC3 (0.42) | TAAR1AOC3SHBGMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6561671 | 0.86 | AOC3 (0.41) | TAAR1AOC3SHBGMEN1KMT2A | |
| SCHEMBL15142926 | 0.80 | APP (0.39) | APPAOC3SHBGMEN1KMT2A | |
| SCHEMBL12015994 | 0.80 | TSHR (0.48) | TAAR1AOC3KIF11MEN1KMT2A | |
| SCHEMBL18545312 | 0.80 | APP (0.39) | APPAOC3SHBGMEN1KMT2A | |
| SCHEMBL19690199 | 0.80 | APP (0.39) | APPAOC3SHBGMEN1KMT2A | |
| SCHEMBL9907013 | 0.80 | APP (0.39) | APPAOC3SHBGMEN1KMT2A | |
| SCHEMBL12171 | 0.79 | TAAR1 (0.62) | TAAR1APPSHBGKIF11MAPT | |
| SCHEMBL7839746 | 0.78 | HTR2C (0.38) | TAAR1AOC3ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010087982-A1 | GLUR2 RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010087982-A1 | GLUR2 RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-08-05 | — | — | WO | disclosed |
| US-20090270508-A1 | GluR2 receptor modulators | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-10-29 | — | — | US | disclosed |
| US-20090270508-A1 | GluR2 receptor modulators | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-10-29 | — | — | US | disclosed |
| US-20090270508-A1 | GluR2 receptor modulators | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-10-29 | — | — | US | disclosed |
| EP-1183232-B1 | MONOFLUOROALKYL DERIVATIVES | LILLY CO ELI (US) | 2007-10-03 | — | — | EP | disclosed |
| EP-1183232-B1 | MONOFLUOROALKYL DERIVATIVES | LILLY CO ELI (US) | 2007-10-03 | — | — | EP | disclosed |
| US-7034045-B1 | Monofluoroalkyl derivatives | ELI LILLY AND COMPANY (US) | 2006-04-25 | — | — | US | disclosed |
| CN-1240677-C | Monofluoroalkyl derivatives | LILLY CO ELI (US) | 2006-02-08 | — | — | CN | disclosed |
| EP-1330233-B1 | METHOD OF TREATING STROKE | LILLY CO ELI (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1292311-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DEPRESSION COMPRISING AN ANTIDEPRESSANT AND AN AMPA RECEPTOR POTENTIATOR | ELI LILLY AND COMPANY (US) | 2003-03-19 | — | — | EP | disclosed |
| WO-2002089848-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES | ELI LILLY AND COMPANY (US) | 2002-11-14 | — | — | WO | disclosed |
| CN-1349497-A | Monofluoroalkyl derivatives | LILLY CO ELI (US) | 2002-05-15 | — | — | CN | disclosed |
| WO-2002032389-A1 | METHOD OF TREATING STROKE | ELI LILLY AND COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002018329-A1 | ACETYLENIC SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-03-07 | — | — | WO | disclosed |
| EP-1183232-A2 | MONOFLUOROALKYL DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2002014275-A2 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION | ELI LILLY AND COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
| WO-2001089530-A2 | COMBINATION THERAPY FOR TREATMENT OF DEPRESSION COMPRISING AN ANTIDEPRESSANT AND AN AMPA RECEPTOR POTENTIATOR | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001089510-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2000066546-A2 | MONOFLUOROALKYL DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270508-A1 | GluR2 receptor modulators | GRM2, GRIK2, GRIN2A | TAAR1 376/4885APP 2410/4885AOC3 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.